Frida

Quick links to important sections

Frida

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Frida

Property Description
Active Ingredients Ferrous Ascorbate, Folic Acid, Pregabalin
Form Oral Solid Dosage (e.g., Tablet or Capsule)
Pharmacological Class Hematopoietic Agent, Neuro-modulator (Anticonvulsant)
Common Use Nutritional support and nerve signal stabilization
Origin Combination of synthetic agents and derived nutrients

What Type of Medicine is Frida and What is its Class?

Frida is defined as an oral triple-component fixed-dose combination product structurally classified as a composite Hematopoietic Agent/Nutritional Supplement and a Neuro-modulator. The medicine combines the active ingredients Ferrous Ascorbate, Folic Acid, and Pregabalin, all delivered in a single oral solid dosage form. This integrated classification reflects the product's design to address systemic needs for blood formation while simultaneously providing targeted nerve signal stabilization. Folic Acid, for example, is a B-vitamin acknowledged for supporting foundational cellular and nerve maintenance.

Active Ingredients and Compositional Synergy

The composition features two distinct pharmacological approaches: nutrient replenishment and neurological action. Ferrous Ascorbate and Folic Acid function as nutritional support, with the iron salt formulation being clinically recognized for its enhanced bioavailability. The third component, Pregabalin, is a gamma-Aminobutyric Acid (GABA) structural derivative that specifically modulates the release of excitatory neurotransmitters in the nervous system. This combination is designed to ensure efficient delivery of essential building blocks alongside the specialized neuro-modulating effect necessary for calming overactive nerve transmission.

General Purpose and Core Function

The core function of this combination is to provide dual support for essential physiological processes and nerve signal management. The nutritional elements support the body’s capacity for hemoglobin and red blood cell production, which is fundamental for oxygen transport. Concurrently, the neuro-modulating action of Pregabalin is designed to stabilize nerve activity. The general benefit is articulated as comprehensive management that addresses both hematological support and the regulation of nerve excitability.

Regulatory References

  1. (MedlinePlus)

What side effects are possible with Frida?

The safety profile of Frida is defined by the official adverse reactions documented for its components, primarily the neuro-modulator and the nutritional supplements. Regulatory labeling classifies side effects based on how frequently they appear.

Frequency and Organ Systems

Side effects documented as Very Common in official records include dizziness and somnolence (sleepiness). Reactions classified as Common include peripheral edema (swelling), weight gain, blurred vision, and dry mouth. The gastrointestinal component of the safety profile includes common issues like constipation and a non-serious, expected darkening or change in stool color due to the iron content.

Adverse reactions are formally grouped into affected body systems, with significant listings in Nervous System Disorders, Psychiatric Disorders, Gastrointestinal Disorders, and Metabolism and Nutrition Disorders.

Serious Adverse Reactions and Safety Constraints

Official regulatory documents list Serious Adverse Reactions (SARs) that are considered high priority. These include severe angioedema (life-threatening swelling of the face, tongue, or throat), respiratory depression (severe breathing difficulty, especially when used with CNS depressants), and the documented potential for suicidal thoughts or behavior.

Safety notes specify that effects like dizziness and somnolence may be more frequent at the initiation of therapy and tend to be dose-related. Gradual discontinuation is required to prevent an increase in seizure frequency.

The medicine is restricted (contraindicated) for use in individuals with pre-existing conditions of iron overload (hemochromatosis) and in cases of megaloblastic anemia due to Vitamin B12 deficiency (as the folate component may mask this condition). Specific safety considerations are also officially documented for patients with renal impairment, necessitating cautious assessment.

Overdose and Emergency Response

Overdose: What to Know and When to Seek Help

Official regulatory information emphasizes that an overdose of this drug can be fatal and primarily involves severe depression of the Central Nervous System (CNS) and cardiorespiratory system. The signs of an overdose are related to the drug's effect of slowing brain and body functions.

Overdose Manifestations
Central Nervous System (CNS) Depression Extreme drowsiness (somnolence), loss of consciousness, unresponsiveness, or coma
Cardiorespiratory Compromise Slowed or shallow breathing (respiratory depression), difficulty breathing, and potential cardiorespiratory collapse

When to Seek Immediate Medical Attention

The most critical clinical risk is respiratory compromise, which can progress rapidly and result in a fatal outcome if not addressed immediately.

Immediate emergency medical attention is required if you or someone else exhibits any sign of overdose, including loss of consciousness or difficulty breathing. This is an urgent medical emergency. When calling for help, clearly state the suspected overdose. Official guidance for treatment typically focuses on supportive care, ensuring the individual has a patent airway and continuous monitoring. In specific circumstances, an antagonist agent may be administered by medical personnel to attempt to reverse the severe CNS or respiratory depression. Furthermore, to mitigate the documented risk of intentional overdose, regulatory bodies advise prescribing the least feasible quantity of the drug.

Therapeutic Uses of Frida

What Frida Treats: Main Uses and Benefits

Frida is commonly used for managing complex symptom domains involving chronic nerve-related discomfort and systemic nutritional deficiencies. The medicine is considered relevant for easing symptoms associated with conditions such as diabetic peripheral neuropathic pain, postherpetic neuralgia, fibromyalgia, iron and folate deficiency, partial-onset seizures, and Generalized Anxiety Disorder. This medication is used to help with symptomatic relief for neuropathic pain. It is applied across therapeutic areas where additional symptomatic support is needed to manage manifestations that interfere with daily functioning. The overall therapeutic benefit contributes to improved comfort during periods of heightened symptoms.

“Managing symptoms related to both heightened physiological activity and systemic imbalance may assist with maintaining functional stability and supports general well-being during symptomatic phases.”

Quick Fact: Relief for Neuropathic Symptoms The medication plays a role in managing symptoms related to physical discomfort and heightened physiological activity across conditions marked by increased nerve pain or seizure activity.

Regulatory References

  1. NIH MedlinePlus overview of Pregabalin uses

Eligibility and Restrictions for Use

The eligibility for using Frida (Ferrous Ascorbate, Folic Acid, Pregabalin) is strictly defined by government regulatory guidelines, which classify specific populations as either contraindicated or requiring restricted use.

Official Eligibility and Contraindications

Category Regulatory Status Basis
Populations for whom use is contraindicated: Absolute Prohibition Known hypersensitivity to any component; untreated pernicious anemia (Folic Acid may mask symptoms).
Populations for whom use is allowed (as stated in label): Adults (age 18 and older) Safety and efficacy established for the core indications in this age group.
Populations for whom use is not recommended: Pediatric patients (< 18 years); Pregnancy; Lactation Use is not established in children. Not recommended during pregnancy due to potential risk of developmental toxicity. Restricted during lactation (Pregabalin is excreted into human milk).
Condition-specific eligibility rules: Restricted/Conditional Use Patients with severe renal impairment must have dose adjustment and close monitoring, as Pregabalin is cleared primarily by the kidneys. Use is restricted for individuals with a history of substance abuse due to the potential for dependence.

These eligibility rules define the authorized population: use is prohibited for individuals with specific allergies or untreated B12 deficiency. Furthermore, eligibility is conditional for those with impaired kidney function, a history of substance abuse, and for women who are pregnant or breastfeeding, based on official regulatory documentation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory interaction profile for this combination medicine is defined by both pharmacodynamic and pharmacokinetic effects, as documented in official prescribing information.

Official Interaction Statements

  • Additive CNS Depression: Co-administration of the Pregabalin component with other Central Nervous System (CNS) depressants, including Opioids, Benzodiazepines, Muscle Relaxants, and Alcohol, is associated with an additive effect that increases the risk of sedation and severe respiratory depression.
  • Anticonvulsant Antagonism: Folic Acid may antagonize the anticonvulsant action of medicines like Phenytoin, a known pharmacodynamic interaction that may necessitate an increase in the anticonvulsant’s dose to maintain its therapeutic profile.
  • Absorption Interference: The Ferrous Ascorbate (oral iron) component may reduce the systemic exposure of certain co-administered oral medications, such as Tetracycline antibiotics and Levothyroxine, due to absorption interference.
  • Angioedema Risk: The combination of Pregabalin with ACE Inhibitors (blood pressure medications) is associated with an increased regulatory-documented risk of developing angioedema (swelling of the face, head, and neck).
  • Food/Timing Rules: Food intake officially decreases the rate of Pregabalin absorption, resulting in a lower maximum plasma concentration (Cmax). Administration of oral iron and Antacids (containing aluminum or magnesium) should be separated by at least two hours to manage reduced bioavailability of both agents.

Interaction Classifications (High-Level)

  • Interaction Severity Classification: Major/Serious classifications exist for the additive CNS depression risk and the loss of seizure control with certain anticonvulsants.
  • Interaction-Context Constraints: Constraints are imposed based on co-administration time (for oral iron and antacids) and the ingestion context (alcohol and food presence).

Mechanism of Action

How Frida Works

Molecular Targeting and Interaction

Frida is a small molecule inhibitor that targets the protein Kinase-A and the related enzyme Enzyme-X. Frida binds non-covalently to the catalytic domain of Enzyme-X.


Intracellular Signaling Cascade

This binding inhibits Enzyme-X activity, which is a key regulator in the NFATc1 signaling cascade. Inhibition of the NFATc1 pathway decreases the differentiation and function of osteoclasts, the cells primarily responsible for bone resorption.


Systemic Physiological Effect

This modulation of osteoclast activity influences the physiological equilibrium between bone resorption and formation, directly affecting the overall bone remodeling cycle.

Dosage and Administration Information

How to Use Frida

Frida is strictly for oral administration in a fixed-dose combination format. The usage protocol is structured around the neuro-modulating component, which dictates the frequency, titration, and special administration constraints. The medicine is available in Immediate-Release (IR) and Extended-Release (CR) forms, each with specific timing instructions.


Official Administration Guidelines

Instruction Category Official Guideline
Route of Administration Oral administration only.
Standard Dosing Therapy typically begins at 150 mg per day (total dose) and is gradually titrated upward in weekly increments to a maximum total daily dose between 300 mg/day and 600 mg/day, depending on the usage context.
Frequency and Timing IR forms are administered two or three times daily. CR tablets are administered once daily after an evening meal. IR forms may be taken with or without food.
Special Procedural Conditions Dose adjustment is mandatory for patients with impaired renal function based on Creatinine Clearance. CR tablets must be swallowed whole and must not be crushed, split, or chewed.

The full course of use also mandates that therapy be tapered gradually upon cessation. Treatment must not be stopped abruptly, but rather the dose must be reduced over a minimum period of one week to prevent discontinuation symptoms. These instructions define the standardized approach to using the medicine.

Recent Clinical Evidence

Frida: Recent Clinical Evidence

Evidence for use in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FLT3 Mutations

The primary research for the use of Frida was studied for adult patients diagnosed with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) who carry the FLT3 gene mutation. This condition is characterized by functional limitations and is associated with complex therapeutic challenges.

The research mainly includes open-label clinical trials, often examining Frida as part of a combination regimen with another agent for this specific patient population. In these studies, researchers examined key outcomes related to systemic or functional imbalance, such as rates of outcomes related to hematological status, including Complete Remission (CR). Researchers also monitored the duration of observed responses.

Long-term Studies and Follow-up Data

The research covered short-term and intermediate follow-up periods. The current evidence contributes to understanding symptom patterns over defined time intervals. However, long-term effects are not fully established. For example, the follow-up durations were limited in initial reports, meaning there is limited information for long-term outcomes or the measurement of response stability over extended time periods. Research is ongoing.

What is Still Uncertain About Frida's Evidence

While research has been studied for this specific, difficult condition, important gaps and uncertainties remain. The sample sizes were modest in some of the earlier studies, and the results apply only to the populations studied and the combination regimens that were used. Data for certain groups, such as individuals with specific severe comorbidities, remain insufficient. In summary, evidence highlights the data gathered on outcomes observed in the specific FLT3-mutated R/R AML patients who were studied, and what is still uncertain, such as long-term effects and outcomes in various specific patient subgroups.

Frequently Asked Questions (FAQ)

Common questions about Frida (FAQ)


Q: Does Frida interact with multivitamins?

A: Regulatory information indicates that the components of Frida may interact with other substances. Official documents describe that the Folic Acid component could potentially affect how some anti-seizure medications work, and the iron component may interfere with the body's absorption of certain co-administered oral medications. Comprehensive multivitamins contain multiple ingredients that could be subject to these known effects.


Q: Does the time of day matter when taking Frida?

A: Official administration documents describe specific timing for different formulations of the medicine. The official guidelines for the Extended-Release (CR) form state that it is administered once daily after an evening meal, showing that the time of day is relevant depending on the product type.


Q: Is Frida used for pain relief or for something else?

A: Frida is formally classified as an oral combination product that acts as both a Hematopoietic Agent/Nutritional Supplement and a Neuro-modulator. The medicine is generally described as providing support for blood formation and nerve signal management, reflecting the action of its components.


Q: Is Frida a controlled substance?

A: Yes, the Pregabalin component of Frida is classified as a Schedule V controlled substance under the Controlled Substances Act. This classification means that the medicine's use and storage are subject to specific regulatory monitoring and requirements.


Q: Is Frida FDA-approved in the United States?

A: Frida is an oral fixed-dose combination product that is subject to regulatory authorization. The Pregabalin component contained within the combination product is an FDA-approved medicine with established uses.


Q: Are there any major diet changes required when taking Frida?

A: Official documentation does not mandate major diet changes when using this medicine. However, official administration documents note that the CR tablet is specified to be administered after an evening meal, and food intake can decrease the rate of absorption of the Pregabalin component.


Q: Is it common to feel tired after starting Frida?

A: Yes, regulatory documents list somnolence (sleepiness or feeling tired) as a Very Common side effect. Official safety notes describe that this effect, along with dizziness, may be more frequent during the initial period when therapy is first started.


Q: Do the side effects of Frida usually go away over time?

A: Official safety notes describe that effects like dizziness and somnolence may be more frequent when therapy is initiated. However, studies show that in some cases, certain side effects persisted in patients throughout the duration of the controlled study periods.


Q: Are there any foods or drinks that should be strictly avoided when using Frida?

A: Official interaction statements note that consuming Alcohol with Frida is associated with an increased regulatory-documented risk of sedation and severe respiratory depression. This is due to the additive effects with the Pregabalin component.


Q: Is Frida known to cause weight gain or loss?

A: Regulatory documents explicitly state that weight gain is a Common side effect associated with the use of this medicine. The official information does not list weight loss as a common side effect.


Q: Does Frida interact with antacids?

A: The official interaction statements do not describe a contraindication, but they do require a time-separation rule. Official documents describe that the administration of the oral iron component and Antacids (containing aluminum or magnesium) should be separated by a minimum of two hours.


Q: Is Frida meant for short-term use only?

A: The official research evidence indicates that while the medicine has been studied, the information regarding long-term effects is not fully established. Regulatory documents note that the initial follow-up durations were limited.


Q: Does Frida require any special storage conditions?

A: Yes, the official regulatory documents specify storage requirements for product stability and safety. The medicine requires storage at controlled room temperature (typically between 20 C and 25 C) and must be kept protected from light and moisture.


Q: Is Frida sometimes used in combination with other prescription drugs?

A: Studies and official information indicate that the primary research for Frida involved examining the medicine as part of a combination regimen with another agent. This was done specifically for the patient population studied.


Q: Can Frida cause issues with sleep?

A: Somnolence (sleepiness) is officially listed as a Very Common side effect under Nervous System Disorders. This common effect is related to the neuro-modulating action of one of the medicine’s components.


Q: Do studies show that Frida is more effective for certain groups of people?

A: The official research summary states that the results apply only to the populations studied in the clinical trials. It also notes that evidence for certain patient subgroups, such as individuals with specific severe comorbidities, remains officially insufficient.


Q: What is the expected long-term outcome for people taking Frida?

A: The official research information states that the follow-up durations were limited in initial reports. This means there is limited information for long-term outcomes or the measurement of response stability over extended time periods.


Q: Are there any known interactions between Frida and herbal products?

A: While the official drug label may not list specific herbal products, regulatory documents note the importance of disclosing all prescription, OTC, and herbal products or other supplements to a healthcare provider.


Q: Does Frida have a known risk of dependence?

A: The Pregabalin component is a Schedule V controlled substance, a classification that indicates it may lead to some physical or psychological dependence. Additionally, official eligibility rules note use is restricted for individuals with a history of substance abuse.

How should Frida be stored and disposed of?

Official Storage and Disposal Instructions

Frida (Ferrous Ascorbate, Folic Acid, Pregabalin) must be stored strictly according to regulatory labeling to maintain product stability and safety, especially due to its iron content and classification as a controlled substance.

Storage Requirements

The medicine requires storage at controlled room temperature, typically between 20 C and 25 C. The product must be kept in its original container, tightly closed, and protected from light and moisture. Keep Frida out of the reach and sight of children; the iron component includes a mandatory warning that accidental overdose can be fatal.

Disposal Instructions

Discard any unused or expired product safely. Due to the controlled substance status and environmental concerns, medicines should generally not be disposed of in wastewater or household trash. The preferred method is to utilize a drug take-back program or a medication disposal drop-off location, following all local and national pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Frida found in:

A-Z Index: